{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T17:41:19Z","timestamp":1786297279331,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,9]]},"DOI":"10.7759\/cureus.114213","type":"journal-article","created":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T16:46:54Z","timestamp":1786294014000},"source":"Crossref","is-referenced-by-count":0,"title":["Fetal and Neonatal Alloimmune Thrombocytopenia in the Middle East: A Confirmed Case Highlighting Immunogenetic Diversity and Evidence-Based Neonatal Management"],"prefix":"10.7759","author":[{"given":"Hamza","family":"Haj Mohamad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rand","family":"Soudan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosul","family":"Makkiyah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohyla","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiullah","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelazeim","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15813","article-title":"Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach","volume":"185","author":"Lieberman L","year":"2019","unstructured":"Lieberman L, Greinacher A, Murphy MF, et al.. Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. Br J Haematol. 2019, 185:549-62. 10.1111\/bjh.15813","journal-title":"Br J Haematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00029-8","article-title":"Rising to the challenge: an international Delphi consensus study on fetal and neonatal alloimmune thrombocytopenia","volume":"12","author":"Pothof R","year":"2025","unstructured":"Pothof R, van den Akker-van Marle EM, de Vos TW, et al.. Rising to the challenge: an international Delphi consensus study on fetal and neonatal alloimmune thrombocytopenia. Lancet Haematol. 2025, 12:e304-11. 10.1016\/S2352-3026(25)00029-8","journal-title":"Lancet Haematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003100","article-title":"ACOG Practice Bulletin No. 207: thrombocytopenia in pregnancy","volume":"133","author":"American College of Obstetricians and Gynecologists","year":"2019","unstructured":"American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 207: thrombocytopenia in pregnancy. Obstet Gynecol. 2019, 133:e181-93. 10.1097\/AOG.0000000000003100","journal-title":"Obstet Gynecol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-3320","article-title":"Incidence and consequences of neonatal alloimmune thrombocytopenia: a systematic review","volume":"133","author":"Kamphuis MM","year":"2014","unstructured":"Kamphuis MM, Paridaans NP, Porcelijn L, Lopriore E, Oepkes D. Incidence and consequences of neonatal alloimmune thrombocytopenia: a systematic review. Pediatrics. 2014, 133:715-21. 10.1542\/peds.2013-3320","journal-title":"Pediatrics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13639","article-title":"Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia","volume":"171","author":"Curtis BR","year":"2015","unstructured":"Curtis BR. Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia. Br J Haematol. 2015, 171:671-82. 10.1111\/bjh.13639","journal-title":"Br J Haematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2012.04.001","article-title":"Foetal\/neonatal alloimmune thrombocytopenia in Egypt; human platelet antigen genotype frequencies and antibody detection and follow-up in pregnancies","volume":"47","author":"Husebekk A","year":"2012","unstructured":"Husebekk A, El Ekiaby M, Gorgy G, et al.. Foetal\/neonatal alloimmune thrombocytopenia in Egypt; human platelet antigen genotype frequencies and antibody detection and follow-up in pregnancies. Transfus Apher Sci. 2012, 47:277-82. 10.1016\/j.transci.2012.04.001","journal-title":"Transfus Apher Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2450\/2013.0220-12","article-title":"Gene frequencies of human platelet alloantigens 1-5 in two Arab populations","volume":"12","author":"Salem AH","year":"2014","unstructured":"Salem AH, Abdel Hamed AE, Abdalla EM, Almawi W. Gene frequencies of human platelet alloantigens 1-5 in two Arab populations. Blood Transfus. 2014, 12:s281-5. 10.2450\/2013.0220-12","journal-title":"Blood Transfus"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V92.7.2280","article-title":"The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening","volume":"92","author":"Williamson LM","year":"1998","unstructured":"Williamson LM, Hackett G, Rennie J, et al.. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood. 1998, 92:2280-7.","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12297","article-title":"Gene frequency of human platelet alloantigens-1 to -6 and -15 in Saudi blood donors","volume":"26","author":"Al-Ouda SK","year":"2016","unstructured":"Al-Ouda SK, Al-Banyan AA, Abdel Gader AG, Bayoumy NM, Al-Gahtani FH. Gene frequency of human platelet alloantigens-1 to -6 and -15 in Saudi blood donors. Transfus Med. 2016, 26:220-4. 10.1111\/tme.12297","journal-title":"Transfus Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/vox.70093","article-title":"Immunogenetic polymorphism of human platelet antigens in the Saudi population: insights into genetic diversity and alloimmune risk","volume":"120","author":"AlSuhaibani O","year":"2025","unstructured":"AlSuhaibani O, Chatti N, AlZahrani S, et al.. Immunogenetic polymorphism of human platelet antigens in the Saudi population: insights into genetic diversity and alloimmune risk. Vox Sang. 2025, 120:1025-33. 10.1111\/vox.70093","journal-title":"Vox Sang"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64469-4","article-title":"Human platelet antigen 1-6, 9 and 15 in the Iranian population: an anthropological genetic analysis","volume":"10","author":"Kazemi MH","year":"2020","unstructured":"Kazemi MH, Malakootikhah F, Momeni-Varposhti Z, Falak R, Delbandi AA, Tajik N. Human platelet antigen 1-6, 9 and 15 in the Iranian population: an anthropological genetic analysis. Sci Rep. 2020, 10:7442. 10.1038\/s41598-020-64469-4","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16398","article-title":"Platelet CD36 deficiency is present in 2.6% of Arabian individuals and can cause NAIT and platelet refractoriness","volume":"61","author":"Flesch BK","year":"2021","unstructured":"Flesch BK, Scherer V, Opitz A, Ochmann O, Janson A, Steitz M, Zeiler T. Platelet CD36 deficiency is present in 2.6% of Arabian individuals and can cause NAIT and platelet refractoriness. Transfusion. 2021, 61:1932-42. 10.1111\/trf.16398","journal-title":"Transfusion"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01208.x","article-title":"Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia","volume":"47","author":"Ghevaert C","year":"2007","unstructured":"Ghevaert C, Campbell K, Walton J, et al.. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion. 2007, 47:901-10. 10.1111\/j.1537-2995.2007.01208.x","journal-title":"Transfusion"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13274","article-title":"Fetal and neonatal alloimmune thrombocytopenia: Predictive factors of intracranial hemorrhage","volume":"56","author":"Delbos F","year":"2016","unstructured":"Delbos F, Bertrand G, Croisille L, Ansart-Pirenne H, Bierling P, Kaplan C. Fetal and neonatal alloimmune thrombocytopenia: Predictive factors of intracranial hemorrhage. Transfusion. 2016, 56:59-66. 10.1111\/trf.13274","journal-title":"Transfusion"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00243-5","article-title":"Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort study","volume":"9","author":"de Vos TW","year":"2022","unstructured":"de Vos TW, Winkelhorst D, \u00c1rnad\u00f3ttir V, et al.. Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort study. Lancet Haematol. 2022, 9:e844-53. 10.1016\/S2352-3026(22)00243-5","journal-title":"Lancet Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41372-019-0360-7","article-title":"Postnatal intervention for the treatment of FNAIT: a systematic review","volume":"39","author":"Baker JM","year":"2019","unstructured":"Baker JM, Shehata N, Bussel J, et al.. Postnatal intervention for the treatment of FNAIT: a systematic review. J Perinatol. 2019, 39:1329-39. 10.1038\/s41372-019-0360-7","journal-title":"J Perinatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12336","article-title":"Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin","volume":"54","author":"Bakchoul T","year":"2014","unstructured":"Bakchoul T, Bassler D, Heckmann M, et al.. Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin. Transfusion. 2014, 54:640-5. 10.1111\/trf.12336","journal-title":"Transfusion"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01268.x","article-title":"Retrospective comparison of maternal vs. HPA-matched donor platelets for treatment of fetal alloimmune thrombocytopenia","volume":"98","author":"Giers G","year":"2010","unstructured":"Giers G, Wenzel F, Fischer J, Stockschl\u00e4der M, Riethmacher R, Lorenz H, Tutschek B. Retrospective comparison of maternal vs. HPA-matched donor platelets for treatment of fetal alloimmune thrombocytopenia. Vox Sang. 2010, 98:423-30. 10.1111\/j.1423-0410.2009.01268.x","journal-title":"Vox Sang"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-739656","article-title":"Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review","volume":"129","author":"Winkelhorst D","year":"2017","unstructured":"Winkelhorst D, Murphy MF, Greinacher A, et al.. Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. Blood. 2017, 129:1538-47. 10.1182\/blood-2016-10-739656","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.15642","article-title":"Prenatal management of pregnancies at risk of fetal neonatal alloimmune thrombocytopenia (FNAIT): scientific impact paper no. 61","volume":"126","author":"Regan F","year":"2019","unstructured":"Regan F, Lees CC, Jones B, Nicolaides KH, Wimalasundera RC, Mijovic A. Prenatal management of pregnancies at risk of fetal neonatal alloimmune thrombocytopenia (FNAIT): scientific impact paper no. 61. BJOG. 2019, 126:e173-85. 10.1111\/1471-0528.15642","journal-title":"BJOG"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/uog.70105","article-title":"Effectiveness of antenatal intravenous immunoglobulin treatment in recurrent fetal and neonatal alloimmune thrombocytopenia","volume":"66","author":"Zloto K","year":"2025","unstructured":"Zloto K, Cohen S, Batsry L, et al.. Effectiveness of antenatal intravenous immunoglobulin treatment in recurrent fetal and neonatal alloimmune thrombocytopenia. Ultrasound Obstet Gynecol. 2025, 66:773-80. 10.1002\/uog.70105","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-006-0389-4","article-title":"Postnatal management of fetal and neonatal alloimmune thrombocytopenia: the role of matched platelet transfusion and IVIG","volume":"166","author":"te Pas AB","year":"2007","unstructured":"te Pas AB, Lopriore E, van den Akker ES, Oepkes D, Kanhai HH, Brand A, Walther FJ. Postnatal management of fetal and neonatal alloimmune thrombocytopenia: the role of matched platelet transfusion and IVIG. Eur J Pediatr. 2007, 166:1057-63. 10.1007\/s00431-006-0389-4","journal-title":"Eur J Pediatr"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004226.pub3","article-title":"Antenatal interventions for fetomaternal alloimmune thrombocytopenia","volume":"2011","author":"Rayment R","year":"2011","unstructured":"Rayment R, Brunskill SJ, Soothill PW, Roberts DJ, Bussel JB, Murphy MF. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev. 2011, 2011:CD004226. 10.1002\/14651858.CD004226.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12671","article-title":"How do we treat fetal and neonatal alloimmune thrombocytopenia?","volume":"54","author":"Bertrand G","year":"2014","unstructured":"Bertrand G, Kaplan C. How do we treat fetal and neonatal alloimmune thrombocytopenia?. Transfusion. 2014, 54:1698-703. 10.1111\/trf.12671","journal-title":"Transfusion"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2461191","article-title":"Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties","volume":"17","author":"Seth NP","year":"2025","unstructured":"Seth NP, Xu R, DuPrie M, et al.. Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties. MAbs. 2025, 17:2461191. 10.1080\/19420862.2025.2461191","journal-title":"MAbs"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/uog.24891","article-title":"Targeting neonatal Fc receptor: potential clinical applications in pregnancy","volume":"60","author":"Moise KJ Jr","year":"2022","unstructured":"Moise KJ Jr, Oepkes D, Lopriore E, Bredius RG. Targeting neonatal Fc receptor: potential clinical applications in pregnancy. Ultrasound Obstet Gynecol. 2022, 60:167-75. 10.1002\/uog.24891","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314466","article-title":"Nipocalimab in early-onset severe hemolytic disease of the fetus and newborn","volume":"391","author":"Moise KJ Jr","year":"2024","unstructured":"Moise KJ Jr, Ling LE, Oepkes D, et al.. Nipocalimab in early-onset severe hemolytic disease of the fetus and newborn. N Engl J Med. 2024, 391:526-37. 10.1056\/NEJMoa2314466","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2312718","article-title":"Neonatal Fc receptor - biology and therapeutics","volume":"392","author":"Bussel JB","year":"2025","unstructured":"Bussel JB, Cines DB, Blumberg RS. Neonatal Fc receptor - biology and therapeutics. N Engl J Med. 2025, 392:1621-35. 10.1056\/NEJMra2312718","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1055\/a-2666-5642","article-title":"Design of a phase 3, multicenter, randomized, placebo-controlled, double-blind study of nipocalimab in pregnancies at risk for fetal and neonatal alloimmune thrombocytopenia","volume":"43","author":"Tiller H","year":"2026","unstructured":"Tiller H, Tiblad E, Baker P, Van Valkenburgh H, Heerwegh D, Keshinro B. Design of a phase 3, multicenter, randomized, placebo-controlled, double-blind study of nipocalimab in pregnancies at risk for fetal and neonatal alloimmune thrombocytopenia. Am J Perinatol. 2026, 43:648-56. 10.1055\/a-2666-5642","journal-title":"Am J Perinatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1055\/a-2753-9323","article-title":"Design of a phase 3, multicenter, randomized, open-label study of nipocalimab or IVIG and prednisone in pregnancies at risk for fetal and neonatal alloimmune thrombocytopenia","volume":"43","author":"Bussel J","year":"2026","unstructured":"Bussel J, Stegmann B, Baker P, et al.. Design of a phase 3, multicenter, randomized, open-label study of nipocalimab or IVIG and prednisone in pregnancies at risk for fetal and neonatal alloimmune thrombocytopenia. Am J Perinatol. 2026, 43:1335-44. 10.1055\/a-2753-9323","journal-title":"Am J Perinatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/479117-fetal-and-neonatal-alloimmune-thrombocytopenia-in-the-middle-east-a-confirmed-case-highlighting-immunogenetic-diversity-and-evidence-based-neonatal-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T16:46:55Z","timestamp":1786294015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/479117-fetal-and-neonatal-alloimmune-thrombocytopenia-in-the-middle-east-a-confirmed-case-highlighting-immunogenetic-diversity-and-evidence-based-neonatal-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,9]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.114213","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,9]]}}}